The 48th Annual Meeting of the Molecular Biology Society of Japan
Advanced Search

Session Details

Symposium

[3AS-17]【J】Nucleic Acids and Pathogenesis of Infectious Diseases

Fri. Dec 5, 2025 9:00 AM - 11:00 AM JST
Fri. Dec 5, 2025 12:00 AM - 2:00 AM UTC
Room 17(Pacifico Yokohama Conference Center 5F, 503)
Organizer: Tomoko Takahashi (Saitama University), Ho Namkoong (Keio University)
Humanity continues to face the threat of infectious diseases, including pandemics, making their control a critical challenge. In recent years, advancements in nucleic acid-based diagnostic technologies and therapies have progressed rapidly, raising strong expectations for their application in the field of infectious diseases. Nucleic acids play a crucial role not only as the genetic information of pathogens but also as factors that regulate the host's immune response. This symposium aims to focus on the role of nucleic acids in infectious diseases and provide a platform to discuss new possibilities in nucleic acid and infectious disease research.
9:00 AM - 9:03 AM JST(12:00 AM - 12:03 AM UTC)

Introduction

9:03 AM - 9:20 AM JST(12:03 AM - 12:20 AM UTC)

[3AS-17-01]Manipulation of mRNA Decay by Nucleic Acids: Implications for Immune Regulation

○Takuya Uehata1 (1. Graduate school of medicine, Kyoto university)
Comment()
9:20 AM - 9:23 AM JST(12:20 AM - 12:23 AM UTC)

Q & A for Each Presentation

9:23 AM - 9:40 AM JST(12:23 AM - 12:40 AM UTC)

[3AS-17-02]Discovery of Ambisense Kolmioviruses: A Strategy for Expanding Coding Capacity in Circular RNA Viruses

○Mai Kishimoto1,2, Sakiho Imai1, Manabu Igarashi3, Masayuki Horie1,2 (1. Graduate School of Veterinary Science, Osaka Metropolitan Univ., 2. Osaka international Research Center for Infectious Diseases, Osaka Metropolitan Univ., 3. International Institute for Zoonosis Control, Hokkaido Univ.)
Comment()
9:40 AM - 9:43 AM JST(12:40 AM - 12:43 AM UTC)

Q & A for Each Presentation

9:43 AM - 9:55 AM JST(12:43 AM - 12:55 AM UTC)

[3AS-17-03(3P-874)]Reduction of cell proliferative capacity of leukemic ATL cells by the removal of HTLV-1 provirus

○Ayano Kawahara1, Ayane Katayama1, Azuki Yasuoka1, Mayuko Yagi1, Satoshi Takeda2, Jun Komano1 (1. Osaka Medical and Pharmaceutical University , 2. Japan Institute for Health Security)
Comment()
9:55 AM - 9:58 AM JST(12:55 AM - 12:58 AM UTC)

Q & A for Each Presentation

9:58 AM - 10:15 AM JST(12:58 AM - 1:15 AM UTC)

[3AS-17-04]Development of Novel Genome Editing Technology for the Treatment of Retroviral Infections

○Asako Yamayoshi1 (1. Institute of Science Tokyo)
Comment()
10:15 AM - 10:18 AM JST(1:15 AM - 1:18 AM UTC)

Q & A for Each Presentation

10:18 AM - 10:35 AM JST(1:18 AM - 1:35 AM UTC)

[3AS-17-05]Development of broad-spectrum antivirals using antisense oligonucleotides targeting host factors

○Tokiko Watanabe1,2,3 (1. Research Institute for Microbial Diseases, The University of Osaka, 2. Center for Infectious Disease Education and Research (CiDER), The University of Osaka, 3. Center for Advanced Modalities and DDS (CAMaD), The University of Osaka)
Comment()
10:35 AM - 10:38 AM JST(1:35 AM - 1:38 AM UTC)

Q & A for Each Presentation

10:38 AM - 10:55 AM JST(1:38 AM - 1:55 AM UTC)

[3AS-17-06]Comprehensive Analysis of Host Genomic Factors Associated with COVID-19 Severity and Vaccine Response

○Ho Namkoong1 (1. Keio University School of Medicine)
Comment()
10:55 AM - 10:58 AM JST(1:55 AM - 1:58 AM UTC)

Q & A for Each Presentation

10:58 AM - 11:00 AM JST(1:58 AM - 2:00 AM UTC)

Conclusion

Back to Category List